Author:
Manley Martin,Jentjens Sander,De Wever Liesbeth,Deroose Christophe M.,Everaerts Wouter,Goffin Karolien
Abstract
Abstract
Purpose
This retrospective analysis aims to study the relationship between tracer uptake in sentinel lymph nodes (SLNs) as measured on SPECT/CT and during intra-operative gamma tracing with a drop-in gamma probe (SENSEI®) in patients who participated in the UZ Leuven cohort of a prospective multicentre clinical trial evaluating the SENSEI® probe for minimally-invasive SLN biopsy (SLNB) in prostate cancer. Correlation of pre- and intraoperative imaging can allow for improved surgical planning, providing important information to guide intraoperative findings.
Methods
Nine patients with histologically proven prostate cancer scheduled for radical prostatectomy (RP) with extended pelvic lymph node dissection (ePLND) were prospectively selected for preoperative lymphoscintigraphy with SPECT/CT the day before surgery after intra-prostatic injection of 240 MBq of 99mTc-nanocolloid under ultrasound guidance. SLNB was performed with the SENSEI® drop-in gamma probe during standard of care RP with ePLND. SLN detection and counts on SPECT/CT and in vivo and ex vivo probe measurements were compared.
Results
The patient-based detection rate of at least one SLN was 100% on SPECT/CT and 100% intraoperatively with the drop-in gamma probe. In total, 29 SLNs were detected with the probe and 32 SLNs on SPECT/CT. The correlation between SPECT/CT counts and in vivo and ex vivo probe measurements was significant but moderate (Pearson r = 0.57, p = 0.002 and r = 0.64, p = 0.0003, respectively).
Conclusions
Drop-in gamma probe measurements showed a moderate correlation with the SPECT/CT counts. SPECT/CT uptake values can be used as an estimate for in vivo detection of SLNs with the probe.
Publisher
Springer Science and Business Media LLC
Reference18 articles.
1. Arnold M, Karim-Kos HE, Coebergh JW, Byrnes G, Antilla A, Ferlay J et al (2015) Recent trends in incidence of five common cancers in 26 European countries since 1988: analysis of the European Cancer Observatory. Eur J Cancer 51:1164–1187
2. Nason GJ, Hamilton RJ (2019) Treating the primary in metastatic prostate cancer: where do we stand? Curr Opin Support Palliat Care 13:243–248
3. Van Der Brouwer OR, Bevers RF, Van Gennep EJ, Horenblas S (2016) Beyond penile cancer, is there a role for sentinel node biopsy in urological malignancies? Clin Transl Imaging 4:395–410
4. Małkiewicz B, Ptaszkowski K, Knecht K, Gurwin A, Wilk K, Kiełb P et al (2021) External validation of the Briganti Nomogram to Predict Lymph Node Invasion in prostate Cancer—setting a new threshold value. Life (Basel) 11:479
5. Lestingi JFP, Guglielmetti GB, Trinh QD, Coelho RF, Jontes J Jr, Bastos DA et al (2021) Extended Versus Limited Pelvic Lymph Node Dissection during Radical Prostatectomy for Intermediate- and high-risk prostate Cancer: early oncological outcomes from a Randomized Phase 3 Trial. Eur Urol 79:595–604